2-5A ligands - A new concept for the treatment of prostate cancer

Nucleosides, Nucleotides and Nucleic Acids

Volumn 26, Issue 10-12, 2007, Pages 1471-1477

  Cramer, Hagen ^a,c   Okicki, James R ^a   Rho, Taikyun ^a   Wang, Xinning ^b   Silverman, Robert H ^b   Heston, Warren D W ^b  

^a Ridgeway Biosystems Inc   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Girindus America Inc   (United States)

Author keywords

Inhibitory activitty; PSMA; RBI 1033

Indexed keywords

ANTINEOPLASTIC AGENT; BLOCKING AGENT; CARBOXYL GROUP; GAMMA GLUTAMYL HYDROLASE; HYDROLASE INHIBITOR; LIGAND; N ACETYLASPARTYLGLUTAMIC ACID; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RBI 1033; UNCLASSIFIED DRUG; ZJ 24;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER THERAPY; COMPARATIVE STUDY; CROSS LINKING; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; MASS SPECTROMETRY; PROSTATE CANCER; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ADENINE NUCLEOTIDES; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; ENDORIBONUCLEASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LIGANDS; MALE; PROSTATIC NEOPLASMS;

EID: 36949039181     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770701542652     Document Type: Article

References (25)

1. Xiang, Y.; Wang, Z.; Murakami, J.; Plummer, S.; Klein, E.A.; Carpten, J.D.; Trent, J.M.; Isaacs, W.B.; Casey, G.; Silverman, R.H. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. Cancer Res. 2003, 63 (20), 6795-6801.
2. Murphy, G.P.; Elgamal, A.A.; Su, S.L.; Bostwick, D.G.; Holmes, E.H. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998, 83 (11), 2259-2269.
3. Israeli, R.S.; Powell, C.T.; Corr, J.G.; Fair, W.R.; Heston, W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 1994, 54 (7), 1807-1811.
4. Wright, G.L., Jr.; Grob, B.M.; Haley, C.; Grossman, K.; Newhall, K.; Petrylak, D.; Troyer, J.; Konchuba, A.; Schellhammer, P.F.; Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48 (2), 326-334.
5. Liu, H.;Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N.H.Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997, 57 (17), 3629-3634.
6. Chang, S.S.; Reuter, V.E.; Heston, W.D.; Bander, N.H.; Grauer, L.S.; Gaudin, P.B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999, 59 (13), 3192-3198.
7. Chang, S.S.; O'Keefe, D.S.; Bacich, D.J.; Reuter, V.E.; Heston, W.D.; Gaudin, P.B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 1999, 5 (10), 2674-2681.
8. Dumas, F.; Gala, J.L.; Berteau, P.; Brasseur, F.; Eschwege, P.; Paradis, V.; Lacour, B.; Philippe, M.; Loric, S. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int. J. Cancer 1999, 80 (6), 799-803.
9. Chang, S.S.; Reuter, V.E.; Heston,W.D.; Gaudin, P.B. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 2001, 57 (4), 801-805.
10. Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997, 3 (1), 81-85.
11. Troyer, J.K.; Beckett, M.L.; Wright, G.L., Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995, 62 (5), 552-558.
12. Kozikowski, A.P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J.H.; Pshenichkin, S.; Wroblewski, J.T. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J. Med. Chem. 2001, 44 (3), 298-301.
13. Jackson, P.F.; Tays, K.L.; Maclin, K.M.; Ko, Y.S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X.C.; Wozniak, K.; Slusher, B.S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J. Med. Chem. 2001, 44 (24), 4170-4175.
14. Tang, H.; Brown, M.; Ye, Y.; Huang, G.; Zhang, Y.; Wang, Y.; Zhai, H.; Chen, X.; Shen, T.Y.; Tenniswood, M. Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase. Biochem. Biophys. Res. Commun. 2003, 307 (1), 8-14.
15. Majer, P.; Jackson, P.F.; Delahanty, G.; Grella, B.S.; Ko, Y.S.; Li, W.; Liu, Q.; Maclin, K.M.; Polakova, J.; Shaffer, K.A.; Stoermer, D.; Vitharana, D.; Wang, E.Y.; Zakrzewski, A.; Rojas, C.; Slusher, B.S.; Wozniak, K.M.; Burak, E.; Limsakun, T.; Tsukamoto, T. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J. Med. Chem. 2003, 46 (10), 1989-1996.
16. Rong, S.B.; Zhang, J.; Neale, J.H.; Wroblewski, J.T.; Wang, S.; Kozikowski, A.P. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors. J. Med. Chem. 2002, 45 (19), 4140-4152.
17. Geselowitz, D.A.; Cramer, H.; Wondrak, E.M.; Player, M.R.; Torrence, P.F. Fluorescence resonance energy transfer analysis of RNase L-catalyzed oligonucleotide cleavage. Antisense Nucleic Acid Drug Dev. 2000, 10 (1), 45-51.
18. Imai, J.; Johnston, M.I.; Torrence, P.F. Chemical modification potentiates the biological activities of 2-5A and its congeners. J. Biol. Chem. 1982, 257 (21), 12739-12745.
19. Defilippi, P.; Huez, G.; Verhaegen-Lawalle, M.; De Clercq, E.; Imai, J.; Torrence, P.; Content, J. Antiviral activity of a chemically stabilized 2-5A analog upon microinjection into HeLa cells. FEBS Lett. 1986, 198 (2), 326-332.
20. Pomper, M.G.; Musachio, J.L.; Zhang, J.; Scheffel, U.; Zhou, Y.; Hilton, J.; Maini, A.; Dannals, R.F.; Wong, D.F.; Kozikowski, A.P. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol. Imaging, 2002, 1 (2), 96-101.
21. Heston, W.D. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997, 49 (3A Suppl), 104-112.
22. Pinto, J.T.; Suffoletto, B.P.; Berzin, T.M.; Qiao, C.H.; Lin, S.; Tong, W.P.; May, F.; Mukherjee, B.; Heston, W.D. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 1996, 2 (9), 1445-1451.
23. Bander, N.H.; Nanus, D.M.; Milowsky, M.I.; Kostakoglu, L.; Vallabahajosula, S.; Goldsmith, S.J. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol. 2003, 30 (5), 667-676.
24. Nanus, D.M.; Milowsky, M.I.; Kostakoglu, L.; Smith-Jones, P.M.; Vallabahajosula, S.; Goldsmith, S.J.; Bander, N.H. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol. 2003, 170 (6 Pt 2), S84-S88; discussion S88-S89.
25. Bander, N.H.; Trabulsi, E.J.; Kostakoglu, L.; Yao, D.; Vallabhajosula, S.; Smith-Jones, P.; Joyce, M.A.; Milowsky, M.; Nanus, D.M.; Goldsmith, S.J. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 2003, 170 (5), 1717-1721.